The preliminary results of the ALT-GIST clinical trial were released at the ASCO Annual Meeting.
ALT-GIST was a phase II trial led by Professor Desmond Yip which investigated the best treatment for patients with metastatic gastro-intestinal stromal tumours (GIST). It examined whether an alternating regimen of two drug therapies, imatinib and regorafenib, was safe and active as a first line treatment for these patients.
The current standard treatment for advanced GIST is imatinib alone. However, GIST patients can build up resistance to imatinib and relapse. The trial investigated if alternating the treatment regimens could delay resistance and improve outcomes for patients.
The preliminary results of ALT-GIST found no meaningful difference for patients between the two treatment regimens after nine months of treatment. Based on these results it can be concluded that the alternating regimen will not improve outcomes for patients with advanced GIST. There was no new or unexpected toxicity observed in the alternating regimen.
ALT-GIST has been conducted through a multinational collaboration involving the Australasian Gastro-Intestinal Trials Group (AGITG0, the European Organisation for the Research and Treatment of Cancer (EORTC), and the Scandinavian Sarcoma Group (SSG).
The study is ongoing, and other outcomes will be reported on in the future. PET scan imaging data as well as blood and tissue samples have been collected for future imaging and biomarker substudies.
The results were presented by Professor Yip in a poster at the 2019 ASCO Annual Meeting. Click here to view the abstract.